Who are Centanafadine SR's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/centanafadine-sr.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Centanafadine SR — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Centanafadine SR (Centanafadine SR) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triple monoamine reuptake inhibitor. Area: Psychiatry / Neurology.

phase 3 Triple monoamine reuptake inhibitor Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT) Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Centanafadine SR (Centanafadine SR) — Otsuka Pharmaceutical Development & Commercialization, Inc.. Centanafadine is a triple monoamine reuptake inhibitor that blocks the reuptake of serotonin, norepinephrine, and dopamine.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Centanafadine SR TARGET	Centanafadine SR	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	Triple monoamine reuptake inhibitor	Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triple monoamine reuptake inhibitor class)

Otsuka Pharmaceutical Development & Commercialization, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Centanafadine SR — Competitive Intelligence Brief. https://druglandscape.com/ci/centanafadine-sr. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing